Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy

被引：30

作者：

Banna, Giuseppe L. ^{[1
]}

Camerini, Andrea ^{[2
,3
]}

Bronte, Giuseppe ^{[4
]}

Anile, Giuseppe ^{[5
]}

Addeo, Alfredo ^{[6
]}

Rundo, Francesco ^{[7
]}

Zanghi, Guido ^{[8
]}

Lal, Rohit ^{[9
]}

Libra, Massimo ^{[10
]}

机构：

[1] Cannizzaro Hosp, Div Med Oncol, Via Messina 829, I-95126 Catania, Italy

[2] Versilia Hosp, Med Oncol, Lido Di Camaiore, Italy

[3] Ist Toscano Tumori, Lido Di Camaiore, Italy

[4] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Italy

[5] Ist Oncol Veneto, Div Med Oncol, Paduva, Italy

[6] Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland

[7] ADG Cent R&D STMicroelect Catania, Catania, Italy

[8] Univ Catania, Policlin Vittorio Emanuele Univ Hosp, Dept Surg, Catania, Italy

[9] Guys & St Thomas Hosp, Lung Canc Unit, London, England

[10] Univ Catania, Pathol & Oncol Sect, Dept Biomed & Biotechnol Sci, Catania, Italy

来源：

ANTICANCER RESEARCH | 2018年 / 38卷 / 06期

关键词：

Non-small cell lung cancer; elderly; unfit; poor performance status; comorbidity; oral metronomic vinorelbine; COMPREHENSIVE GERIATRIC ASSESSMENT; PHASE-II TRIAL; ELDERLY-PATIENTS; PERFORMANCE STATUS; CLINICAL-TRIALS; INDUCTION CHEMOTHERAPY; 1ST-LINE TREATMENT; SINGLE-AGENT; SOLID TUMORS; METAANALYSIS;

D O I：

10.21873/anticanres.12647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To explore the feasibility and activity of oral metronomic vinorelbine patients with advanced NSCLC not eligible to standard chemotherapy because of old age (>= 70 years), and/or poor Eastern Cooperative Oncology Group performance status (>= 2), and/or extensive brain or bone disease, and/or active comorbidities (>= 2) requiring for pharmacological treatment. Patients and Methods: In a prospective phase II not randomized study, patients with stage IV NSCLC unfit to chemotherapy were treated with oral metronomic vinorelbine at 30 mg fixed dose three times a week until disease progression. Results: Fifty patients were treated, 19 (38%) in the first-line setting. Five patients (11%) experienced a grade 3 toxicity; no grade 4 toxicity occurred. Overall disease control rate was 32%, 44% and 26% in first and subsequent lines, respectively (p=0.39). Median OS and PFS were 7.3 months (95% confidence interval [C1]=4.7-10.0) and 2.7 months (95%CI=2.0-3.4), respectively. Conclusion: These data support the activity and safety of metronomic vinorelbine in a relevant proportion of patients usually excluded from any specific treatment.

引用

页码：3689 / 3697

页数：9

共 61 条

[1]

Agresti A., 1992, STAT SCI, V7, P131, DOI [10.1214/ss/1177011454, DOI 10.1214/SS/1177011454]

[2] Metronomics: towards personalized chemotherapy? [J].

Andre, Nicolas ;

Carre, Manon ;

Pasquier, Eddy .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (07) :413-431

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology [J].

Aurilio, Gaetano ;

Gori, Stefania ;

Nole, Franco ;

Pruneri, Giancarlo ;

Coati, Francesca ;

Torri, Valter ;

Lunardi, Gianluigi ;

Atzori, Francesco ;

La Verde, Nicla ;

Banna, Giuseppe Luigi ;

Rossi, Antonio ;

Del Mastro, Lucia ;

Di Fabio, Francesca ;

Marcon, Ilaria ;

Gebbia, Vittorio ;

Loupakis, Fotios ;

Orlando, Laura ;

Ciuffreda, Libero ;

Amadio, Placido ;

Luppi, Gabriele ;

Redana, Stefania ;

Filippelli, Gianfranco ;

Gentile, Annalisa ;

Collova, Elena .

TUMORI, 2016, 102 (01) :108-113

[5] Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer [J].

Banna, Giuseppe L. ;

Parra, Hector Jose Soto ;

Castaing, Marine ;

Dieci, Maria Vittoria ;

Anile, Giuseppe ;

Nicolosi, Maurizio ;

Strano, Salvatore ;

Marletta, Francesco ;

Guarneri, Valentina ;

Conte, Pierfranco ;

Lal, Rohit .

ANTICANCER RESEARCH, 2017, 37 (07) :3723-3728

[6] Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer [J].

Banna, Giuseppe Luigi ;

Anile, Giuseppe ;

Russo, Giorgio ;

Vigneri, Paolo ;

Castaing, Marine ;

Nicolosi, Maurizio ;

Strano, Salvatore ;

Gieri, Stefania ;

Spina, Rosaria ;

Patane, Domenico ;

Calcara, Giacomo ;

Fraggetta, Filippo ;

Marletta, Francesco ;

Stefano, Alessandro ;

Ippolito, Massimo .

ONCOLOGY, 2017, 92 (01) :39-47

[7]

Banna GL, 2015, FUTURE ONCOL, V11, P2375, DOI [10.2217/FON.15.172, 10.2217/fon.15.172]

[8] A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer [J].

Banna, Giuseppe Luigi ;

Lipari, Helga ;

Nicolosi, Maurizio ;

Basile, Antonio ;

Fraggetta, Filippo ;

Vaglica, Marina ;

Marletta, Francesco ;

Urso, Orazio Ezio ;

Ippolito, Massimo ;

Terminella, Alberto ;

Saita, Salvatore .

MEDICAL ONCOLOGY, 2013, 30 (02)

[9] Anticancer oral therapy: Emerging related issues [J].

Banna, Giuseppe Luigi ;

Collova, Elena ;

Gebbia, Vittorio ;

Lipari, Helga ;

Giuffrida, Pietro ;

Cavallaro, Sebastiano ;

Condorelli, Rosaria ;

Buscarino, Calogero ;

Tralongo, Paolo ;

Ferrau, Francesco .

CANCER TREATMENT REVIEWS, 2010, 36 (08) :595-605

[10] Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status [J].

Bilir, C. ;

Durak, S. ;

Kizilkaya, B. ;

Hacibekiroglu, I. ;

Nayir, E. ;

Engin, H. .

CURRENT ONCOLOGY, 2017, 24 (03) :E199-E204

← 1 2 3 4 5 6 7 →